fbpx

Goldman Sachs Closes $650M Fund To Invest In ‘Golden Era’ Pf Biotech Innovation

Goldman Sachs’s new fund—its first dedicated to life sciences—will focus on early- to mid-stage therapeutics companies with multiple assets. Genetic medicine, cell therapy, immunotherapy, and artificial intelligence are among the areas of investment interest for the firm.

The post Goldman Sachs Closes $650M Fund To Invest In ‘Golden Era’ Pf Biotech Innovation appeared first on Above the Law.

Related Articles

Responses

Your email address will not be published. Required fields are marked *